1w96
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1w96.gif|left|200px]] | [[Image:1w96.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1w96", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | + | or leave the SCENE parameter empty for the default display. | |
| - | | | + | --> |
| - | | | + | {{STRUCTURE_1w96| PDB=1w96 | SCENE= }} |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''CRYSTAL STRUCTURE OF BIOTIN CARBOXYLASE DOMAIN OF ACETYL-COENZYME A CARBOXYLASE FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH SORAPHEN A''' | '''CRYSTAL STRUCTURE OF BIOTIN CARBOXYLASE DOMAIN OF ACETYL-COENZYME A CARBOXYLASE FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH SORAPHEN A''' | ||
| Line 31: | Line 28: | ||
[[Category: Volrath, S L.]] | [[Category: Volrath, S L.]] | ||
[[Category: Weatherly, S C.]] | [[Category: Weatherly, S C.]] | ||
| - | [[Category: | + | [[Category: Allosteric inhibition]] |
| - | [[Category: | + | [[Category: Diabetes]] |
| - | [[Category: | + | [[Category: Fatty acid metabolism]] |
| - | [[Category: | + | [[Category: Obesity]] |
| - | [[Category: | + | [[Category: Polyketide]] |
| - | [[Category: | + | [[Category: Structure-based drug design]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 13:19:49 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 10:19, 3 May 2008
CRYSTAL STRUCTURE OF BIOTIN CARBOXYLASE DOMAIN OF ACETYL-COENZYME A CARBOXYLASE FROM SACCHAROMYCES CEREVISIAE IN COMPLEX WITH SORAPHEN A
Overview
Acetyl-coenzyme A carboxylases (ACCs) have crucial roles in fatty acid metabolism. Soraphen A, a macrocyclic polyketide natural product, is a nanomolar inhibitor against the biotin carboxylase (BC) domain of human, yeast, and other eukaryotic ACCs. Here we report the crystal structures of the yeast BC domain, alone and in complex with soraphen A. Soraphen has extensive interactions with an allosteric site, about 25 A from the active site. The specificity of soraphen is explained by large structural differences between the eukaryotic and prokaryotic BC in its binding site, confirmed by our studies on the effects of single-site mutations in this binding site. Unexpectedly, our structures suggest that soraphen may bind in the BC dimer interface and inhibit the BC activity by disrupting the oligomerization of this domain. Observations from native gel electrophoresis confirm this structural insight. The structural information provides a foundation for structure-based design of new inhibitors against these enzymes.
About this Structure
1W96 is a Single protein structure of sequence from Saccharomyces cerevisiae. Full crystallographic information is available from OCA.
Reference
A mechanism for the potent inhibition of eukaryotic acetyl-coenzyme A carboxylase by soraphen A, a macrocyclic polyketide natural product., Shen Y, Volrath SL, Weatherly SC, Elich TD, Tong L, Mol Cell. 2004 Dec 22;16(6):881-91. PMID:15610732 Page seeded by OCA on Sat May 3 13:19:49 2008
